Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 232

1.

Myxoid Liposarcoma With Heterologous Components: Dedifferentiation or Metaplasia? A FISH-documented and CGH-documented Case Report.

Weingertner N, Neuville A, Chibon F, Ray-Coquard I, Marcellin L, Ghnassia JP.

Appl Immunohistochem Mol Morphol. 2015 Mar;23(3):230-5. doi: 10.1097/PAI.0000000000000008.

PMID:
25747531
2.

Trabectedin in patients with advanced soft tissue sarcoma: A retrospective national analysis of the French Sarcoma Group.

Le Cesne A, Ray-Coquard I, Duffaud F, Chevreau C, Penel N, Bui Nguyen B, Piperno-Neumann S, Delcambre C, Rios M, Chaigneau L, Le Maignan C, Guillemet C, Bertucci F, Bompas E, Linassier C, Olivier T, Kurtz JE, Even C, Cousin P, Yves Blay J; French Sarcoma Group.

Eur J Cancer. 2015 Feb 23. pii: S0959-8049(15)00014-3. doi: 10.1016/j.ejca.2015.01.006. [Epub ahead of print]

PMID:
25727882
3.

Interruption versus continuation of trabectedin in patients with soft-tissue sarcoma (T-DIS): a randomised phase 2 trial.

Cesne AL, Blay JY, Domont J, Tresch-Bruneel E, Chevreau C, Bertucci F, Delcambre C, Saada-Bouzid E, Piperno-Neumann S, Bay JO, Mir O, Ray-Coquard I, Ryckewaert T, Valentin T, Isambert N, Italiano A, Clisant S, Penel N.

Lancet Oncol. 2015 Mar;16(3):312-9. doi: 10.1016/S1470-2045(15)70031-8. Epub 2015 Feb 11.

PMID:
25680558
4.

[Molecular biology of sarcoma and therapeutic choices].

Dufresne A, Cassier P, Heudel P, Pissaloux D, Wang Q, Blay JY, Ray-Coquard I.

Bull Cancer. 2015 Jan;102(1):6-16. doi: 10.1016/j.bulcan.2014.12.005. Epub 2015 Jan 13. Review. French.

PMID:
25609490
5.

Clinical trial designs for rare diseases: studies developed and discussed by the International Rare Cancers Initiative.

Bogaerts J, Sydes MR, Keat N, McConnell A, Benson A, Ho A, Roth A, Fortpied C, Eng C, Peckitt C, Coens C, Pettaway C, Arnold D, Hall E, Marshall E, Sclafani F, Hatcher H, Earl H, Ray-Coquard I, Paul J, Blay JY, Whelan J, Panageas K, Wheatley K, Harrington K, Licitra L, Billingham L, Hensley M, McCabe M, Patel PM, Carvajal R, Wilson R, Glynne-Jones R, McWilliams R, Leyvraz S, Rao S, Nicholson S, Filiaci V, Negrouk A, Lacombe D, Dupont E, Pauporté I, Welch JJ, Law K, Trimble T, Seymour M.

Eur J Cancer. 2015 Feb;51(3):271-81. doi: 10.1016/j.ejca.2014.10.027. Epub 2014 Dec 24.

6.

New clinical research strategies for rare gynecologic malignancies.

Ray-Coquard I, Pujade-Lauraine E, Ledermann JA.

Curr Opin Obstet Gynecol. 2015 Feb;27(1):53-7. doi: 10.1097/GCO.0000000000000144.

PMID:
25490380
7.

The off-label use of targeted therapies in sarcomas: the OUTC'S program.

Eberst L, Cropet C, Le Cesne A, Pautier P, Penel N, Adenis A, Chevreau C, Bay JO, Collard O, Cupissol D, Duffaud F, Gentet JC, Piperno-Neumann S, Marec-Berard P, Bompas E, Thyss A, Chaigneau L, Cassier P, Bertucci F, Blay JY, Ray-Coquard I.

BMC Cancer. 2014 Nov 24;14:870. doi: 10.1186/1471-2407-14-870.

8.

Transferability of health cost evaluation across locations in oncology: cluster and principal component analysis as an explorative tool.

Perrier L, Buja A, Mastrangelo G, Baron PS, Ducimetière F, Pauwels PJ, Rossi CR, Gilly FN, Martin A, Favier B, Farsi F, Laramas M, Baldo V, Collard O, Cellier D, Blay JY, Ray-Coquard I.

BMC Health Serv Res. 2014 Nov 18;14:537. doi: 10.1186/s12913-014-0537-x.

9.

Gynecologic Cancer InterGroup (GCIG) consensus review for cervical adenocarcinoma.

Fujiwara H, Yokota H, Monk B, Treilleux I, Devouassoux-Shisheboran M, Davis A, Kim JW, Mahner S, Stany M, Pignata S, Ray-Coquard I, Fujiwara K.

Int J Gynecol Cancer. 2014 Nov;24(9 Suppl 3):S96-101. doi: 10.1097/IGC.0000000000000263.

PMID:
25341589
10.

Gynecologic Cancer InterGroup (GCIG) consensus review for ovarian and primary peritoneal low-grade serous carcinomas.

Gourley C, Farley J, Provencher DM, Pignata S, Mileshkin L, Harter P, Maenpaa J, Kim JW, Pujaide-Lauraine E, Glasspool RM, Ray-Coquard I, Gershenson D.

Int J Gynecol Cancer. 2014 Nov;24(9 Suppl 3):S9-13. doi: 10.1097/IGC.0000000000000257.

PMID:
25341587
11.

Gynecologic Cancer InterGroup (GCIG) consensus review for high-grade undifferentiated sarcomas of the uterus.

Pautier P, Nam EJ, Provencher DM, Hamilton AL, Mangili G, Siddiqui NA, Westermann AM, Reed NS, Harter P, Ray-Coquard I.

Int J Gynecol Cancer. 2014 Nov;24(9 Suppl 3):S73-7. doi: 10.1097/IGC.0000000000000281.

PMID:
25341584
12.

Gynecologic Cancer InterGroup (GCIG) consensus review: uterine and ovarian leiomyosarcomas.

Hensley ML, Barrette BA, Baumann K, Gaffney D, Hamilton AL, Kim JW, Maenpaa JU, Pautier P, Siddiqui NA, Westermann AM, Ray-Coquard I.

Int J Gynecol Cancer. 2014 Nov;24(9 Suppl 3):S61-6. doi: 10.1097/IGC.0000000000000261.

PMID:
25341583
13.

Gynecologic Cancer InterGroup (GCIG) consensus review for uterine and ovarian carcinosarcoma.

Berton-Rigaud D, Devouassoux-Shisheboran M, Ledermann JA, Leitao MM, Powell MA, Poveda A, Beale P, Glasspool RM, Creutzberg CL, Harter P, Kim JW, Reed NS, Ray-Coquard I.

Int J Gynecol Cancer. 2014 Nov;24(9 Suppl 3):S55-60. doi: 10.1097/IGC.0000000000000228.

PMID:
25341582
14.

Gynecologic Cancer InterGroup (GCIG) consensus review for ovarian sex cord stromal tumors.

Ray-Coquard I, Brown J, Harter P, Provencher DM, Fong PC, Maenpaa J, Ledermann JA, Emons G, Rigaud DB, Glasspool RM, Mezzanzanica D, Colombo N.

Int J Gynecol Cancer. 2014 Nov;24(9 Suppl 3):S42-7. doi: 10.1097/IGC.0000000000000249.

PMID:
25341579
15.

Gynecologic Cancer InterGroup (GCIG) consensus review for carcinoid tumors of the ovary.

Reed NS, Gomez-Garcia E, Gallardo-Rincon D, Barrette B, Baumann K, Friedlander M, Kichenadasse G, Kim JW, Lorusso D, Mirza MR, Ray-Coquard I.

Int J Gynecol Cancer. 2014 Nov;24(9 Suppl 3):S35-41. doi: 10.1097/IGC.0000000000000265.

PMID:
25341578
16.

Gynecologic Cancer InterGroup (GCIG) consensus review for ovarian small cell cancers.

Reed NS, Pautier P, Åvall-Lundqvist E, Choi CH, du Bois A, Friedlander M, Fyles A, Kichenadasse G, Provencher DM, Ray-Coquard I.

Int J Gynecol Cancer. 2014 Nov;24(9 Suppl 3):S30-4. doi: 10.1097/IGC.0000000000000293.

PMID:
25341577
17.

International Journal of Gynecological Cancer. Editorial.

Ray-Coquard I, Ledermann J.

Int J Gynecol Cancer. 2014 Nov;24(9 Suppl 3):S2-4. doi: 10.1097/IGC.0000000000000234. No abstract available.

PMID:
25341575
18.

Tumor genotype is an independent prognostic factor in primary gastrointestinal stromal tumors of gastric origin: a european multicenter analysis based on ConticaGIST.

Wozniak A, Rutkowski P, Schöffski P, Ray-Coquard I, Hostein I, Schildhaus HU, Le Cesne A, Bylina E, Limon J, Blay JY, Siedlecki JA, Wardelmann E, Sciot R, Coindre JM, Debiec-Rychter M.

Clin Cancer Res. 2014 Dec 1;20(23):6105-16. doi: 10.1158/1078-0432.CCR-14-1677. Epub 2014 Oct 7.

PMID:
25294914
19.

Oral ridaforolimus plus trastuzumab for patients with HER2+ trastuzumab-refractory metastatic breast cancer.

Seiler M, Ray-Coquard I, Melichar B, Yardley DA, Wang RX, Dodion PF, Lee MA.

Clin Breast Cancer. 2015 Feb;15(1):60-5. doi: 10.1016/j.clbc.2014.07.008. Epub 2014 Aug 17.

PMID:
25239224
20.

Incorporation of pazopanib in maintenance therapy of ovarian cancer.

du Bois A, Floquet A, Kim JW, Rau J, del Campo JM, Friedlander M, Pignata S, Fujiwara K, Vergote I, Colombo N, Mirza MR, Monk BJ, Kimmig R, Ray-Coquard I, Zang R, Diaz-Padilla I, Baumann KH, Mouret-Reynier MA, Kim JH, Kurzeder C, Lesoin A, Vasey P, Marth C, Canzler U, Scambia G, Shimada M, Calvert P, Pujade-Lauraine E, Kim BG, Herzog TJ, Mitrica I, Schade-Brittinger C, Wang Q, Crescenzo R, Harter P.

J Clin Oncol. 2014 Oct 20;32(30):3374-82. doi: 10.1200/JCO.2014.55.7348. Epub 2014 Sep 15.

PMID:
25225436
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk